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Introduction: OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA) was a randomized,
double-blind comparison of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch in patients with mild-to-moderate
Alzheimer’s disease who declined despite open-label treatment with 9.5 mg/24 h patch. Over 48 weeks of
double-blind treatment, high-dose patch produced greater functional and cognitive benefits compared with
9.5 mg/24 h patch.
Methods: Using OPTIMA data, a post-hoc responder analysis was performed to firstly, compare the proportion
of patients demonstrating improvement or absence of decline with 13.3 mg/24 h versus 9.5 mg/24 h patch; and
secondly, identify predictors of improvement or absence of decline. ‘Improvers’ were patients who improved on
the Alzheimer’s Disease Assessment Scale–cognitive subscale (ADAS-cog) by ≥4 points from baseline, and did
not decline on the instrumental domain of the Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale
(ADCS-IADL). ‘Non-decliners’ were patients who did not decline on either scale.
Results: Overall, 265 patients randomized to 13.3 mg/24 h and 271 to 9.5 mg/24 h patch met the criteria for inclusion
in the intention-to-treat population and were included in the analyses. Significantly more patients were ‘improvers’ with
13.3 mg/24 h compared with 9.5 mg/24 h patch at Weeks 24 (44 (16.6%) versus 19 (7.0%); P < 0.001) and 48 (21 (7.9%)
versus 10 (3.7%); P = 0.023). A significantly greater proportion of patients were ‘non-decliners’ with 13.3 mg/24 h
compared with 9.5 mg/24 h patch at Week 24 (71 (26.8%) versus 44 (16.2%); P = 0.002). At Week 48, there was a
trend in favor of 13.3 mg/24 h patch. Functional and cognitive assessment scores at double-blind baseline did
not consistently predict effects at Weeks 24 or 48.
Conclusion: More patients with mild-to-moderate Alzheimer’s disease who are titrated to 13.3 mg/24 h rivastigmine
patch at time of decline are ‘improvers’ or ‘non-decliners’ i.e. show responses on cognition and activities of daily living
compared with patients remaining on 9.5 mg/24 h patch.
Trial registration: Clinicaltrials.gov identifier: NCT00506415; registered July 20, 2007.Introduction
The cholinesterase inhibitors (ChEIs), galantamine, done-
pezil and rivastigmine, remain the predominant treat-
ment for providing symptomatic relief for patients with
mild-to-moderate Alzheimer’s disease (AD). To ensure
the best outcome for the patient, it is important that use* Correspondence: JLMOLI@clinic.ub.es
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of disease progression; suboptimal dosing of ChEI
therapy may be associated with a reduced chance of
response [1]. Patients who ‘respond’ to treatment are
generally regarded as those who demonstrate a clinic-
ally meaningful benefit on an outcome measure. In
neurodegenerative diseases, a treatment response refers
to short-term improvement, longer-term stabilization or
a slowed decline in one or more clinically relevant
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sured by evaluation of cognitive factors, such as learning
and memory. The Alzheimer’s Disease Assessment
Scale–cognitive subscale (ADAS-cog) [3] is the stand-
ard neuropsychological measure in trials involving pa-
tients with mild-to-moderate AD [4,5]. It is important
that functional decline is also measured to assess the
ability to perform clinically meaningful activities of
daily living (ADL). The Alzheimer’s Disease Cooperative
Study (ADCS)-ADL scale is among the instruments
most commonly used to assess function in AD-type
dementia [6,7].
In clinical trials, outcomes may be measured as: the
mean difference in the total score on a given scale be-
tween active treatment and comparator groups; the delay
to reaching specific milestones; or the percentage of
‘responders’ to treatment compared with a comparator
treatment group or placebo. The criterion usually ap-
plied for a ‘responder’ is a four-point or more improve-
ment on the ADAS-cog [8], as this is generally accepted
to represent a clinically relevant change on an individual
basis in patients with mild-to-moderate AD [9]. In
addition, for a population of patients who, without treat-
ment, display continuous decline, achieving any im-
provement or temporary stability on the ADAS-cog and
other assessments may represent a significant thera-
peutic benefit. Therefore, it is important to assess not
just those who improve on the ADAS-cog, but also
those who do not decline. On the ADCS-ADL, a re-
sponder can be defined as a patient who improves or is
stabilized in the course of a randomized clinical trial. It
is also important to identify factors that may influence
the likelihood of receiving a benefit from treatment, as
patients may vary in their response to treatment accord-
ing to their clinical characteristics [10,11].
Here, we present a post-hoc responder analysis of the
instrumental domain of the ADCS-ADL scale (ADCS-
IADL) data and the ADAS-cog data from the OPtimizing
Transdermal Exelon In Mild-to-moderate Alzheimer’s
disease (OPTIMA) clinical study (clinicaltrials.gov identi-
fier NCT00506415). The aim of this analysis was firstly to
identify the proportion of patients who demonstrated
improvement or absence of decline with the 13.3 mg/24 h
(15 cm2) versus the 9.5 mg/24 h (10 cm2) rivastigmine patch
and, secondly to identify which patient characteristics are
predictive of treatment response or non-decline.
Methods
Study population and study design
Detailed methodology of the OPTIMA study has been
published previously [12]. Briefly, eligible patients were
50- to 85-years old, with a diagnosis of mild-to-moderate,
probable AD according to the criteria of the National
Institute of Neurological and Communicative Disordersand Stroke, and the Alzheimer’s Disease and Related
Disorders Association (NINCDS/ADRDA) [13] and a
Mini-Mental State Examination (MMSE) score of ≥10
and ≤24 [14].
Patients who met pre-specified functional decline cri-
teria (per physicians’ judgment) and cognitive decline
criteria (≥3 point decline from baseline, or ≥2 point de-
cline from the previous visit, in MMSE score) during up
to 48 weeks of initial open-label (IOL) treatment with
the 9.5 mg/24 h rivastigmine patch, subsequently en-
tered a 48-week double-blind (DB) phase of the trial. In
the DB phase, patients were randomized to treatment
with either the 13.3 mg/24 h or the 9.5 mg/24 h rivastig-
mine patch [12]. The OPTIMA study protocol was
reviewed by the representative ethics committee for each
participating center (see Additional file 1). The study
was designed and implemented in accordance with Good
Clinical Practice and the local regulations and ethical
principles laid down in the Declaration of Helsinki [12].
All patients, or a legally acceptable representative, and
caregivers provided written informed consent prior to
participating in the study.
Of 1,584 patients enrolled into the IOL phase of the
study, 567 met the pre-specified decline criteria during
the IOL phase and were randomized into the DB
phase; 280 to the 13.3 mg/24 h patch and 287 to the
9.5 mg/24 h patch [12]. The mean MMSE score ±
standard deviation (SD) at baseline of the IOL phase,
for those patients who declined during the IOL phase and,
hence, were randomized into the DB phase, was 16.9 ± 3.6.
At DB-baseline (DB-BL), the mean ± SD MMSE score
was 14.1 ± 4.8 in the 13.3 mg/24 h patch group and
14.2 ± 4.6 in the 9.5 mg/24 h patch group, indicating
that this represented a declining population [12].
Study outcomes and responder definition
The co-primary outcomes of the OPTIMA study were
the change from DB-BL to Week 48 in ADAS-cog and
ADCS-IADL scores. In this post-hoc analysis, responder
analyses were conducted in each treatment group, on
data collected during the DB-treatment phase, by apply-
ing definitions for ‘improvement’ and ‘non-decline’ using
ADAS-cog and ADCS-IADL criteria, in order to assess
outcomes of both cognition and functional response.
The percentages of patients with change from DB-BL in
each responder category at Weeks 24 and 48 were com-
pared between treatment groups (13.3 mg/24 h versus
9.5 mg/24 h patch).
On the ADAS-cog, where an increase in points
represents decline: a clinically relevant improvement
is assessed as a reduction in ADAS-cog score from
DB-BL of four points or more; a lack of decline in-
cludes patients with clinically relevant improvements
from DB-BL, non-clinically relevant improvements from
Figure 1 Responder analyses for the individual assessment
scales. (A) Compared with the 9.5 mg/24 h patch, the 13.3 mg/24 h
patch was associated with a significantly higher proportion of patients
with ≥4 point improvement on the ADAS-cog at both weeks
24 and 48. *P <0.05, 13.3 mg/24 h versus 9.5 mg/24 h patch.
(B) Compared with the 9.5 mg/24 h patch, the 13.3 mg/24 h patch
was associated with a significantly higher proportion of patients
who showed no decline on the ADCS-IADL at Week 24. *P <0.05,
13.3 mg/24 h versus 9.5 mg/24 h patch. ADAS-cog, Alzheimer’s
Disease Assessment Scale–cognitive subscale; ADCS-IADL,
Instrumental domain of the Alzheimer’s Disease Cooperation
Study–Activities of Daily Living scale.
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no change from DB-BL in ADAS-cog score).
On the ADCS-IADL, where a decrease in points rep-
resents decline: a lack of decline is assessed as no change
or any improvement from DB-BL (that is, change from
DB-BL ≥0 points).
For the combined analysis, two groups were identified:
those who improved on ADAS-cog and did not decline
on ADCS-IADL (‘improvers’) and a wider group who
did not decline on either scale (‘non-decliners’, which en-
compasses the ‘improvers’). Therefore, an ‘improver’ was
defined as a patient who experienced an improvement
from DB-BL in ADAS-cog score ≥4 points and no de-
cline or a change from DB-BL in ADCS-IADL score ≥0
points; a ‘non-decliner’ was defined as a patient who ex-
perienced no decline or a change from DB-BL in ADAS-
cog score ≤0 points and no decline or a change from
DB-BL in ADCS-IADL score ≥0 points. Predictors of
these combined response outcomes (‘improvers’ and
‘non-decliners’) were investigated at Weeks 24 and 48.
Analysis
Patient data were analyzed according to the randomized
treatment (13.3 mg/24 h or 9.5 mg/24 h patch). The pri-
mary analysis of this study was based on the intention-
to-treat population in the DB phase (ITT-DB) using a
last-observation-carried-forward (LOCF) imputation. The
ITT-DB population with an LOCF imputation consisted of
all patients who received at least one dose of study drug
who also had at least one post-randomization assessment
for both the ADAS-cog and ADCS-IADL.
Predictors of a combined response were investigated
using a stepwise logistic regression model on both the
combined criteria for improvement (‘improvers’) and the
combined criteria for response (‘non-decliners’), with the
following potential explanatory variables in addition to
treatment: gender, ADAS-cog score at DB-BL, ADCS-
IADL score at DB-BL, MMSE score at DB-BL of ≤12,
and body weight category (<50 kg, 50 to 80 kg, >80 kg).
Variables included in the final model were those with a
P-value <0.15. Odds ratios (ORs) were calculated.
Results
Study population
In total, 265 patients randomized to the 13.3 mg/24 h
patch and 271 patients randomized to the 9.5 mg/24 h
patch met the criteria for inclusion in the ITT-DB popula-
tion and were included in the present analysis.
Response on the ADAS-cog and ADCS-IADL when
analyzed separately
A significantly greater proportion of patients receiving
the 13.3 mg/24 h compared with the 9.5 mg/24 h patch
demonstrated ≥4 points improvement on the ADAS-cogat Week 24 (n = 66 (24.9%) versus n = 39 (14.4%), P =
0.001) and at Week 48 (n = 42 (15.8%) versus n = 26
(9.6%), P = 0.020) (Figure 1A). A significantly higher pro-
portion of patients receiving the 13.3 mg/24 h patch com-
pared with the 9.5 mg/24 h patch showed no decline on
the ADCS-IADL at Week 24 (n = 126 (47.5%) versus n =
102 (37.6%), P = 0.015). The difference at Week 48 was
not statistically significant (n = 84 (31.7%) versus n = 68
(25.1%), P = 0.076); the difference was numerically in favor
of the high-dose 13.3 mg/24 h patch group (Figure 1B).
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ADCS-IADL
Baseline mean scores were comparable between the
13.3 mg/24 h patch and the 9.5 mg/24 h patch groups
for the ADAS-cog (34.4 versus 34.9, respectively) and
ADCS-IADL (27.5 versus 25.8, respectively). A signifi-
cantly higher percentage of patients receiving the
13.3 mg/24 h patch compared with those receiving the
9.5 mg/24 h patch were ‘improvers’, demonstrating
improvement of ≥4 points on the ADAS-cog plus no
decline on the ADCS-IADL, at both Week 24 (n = 44
(16.6%) versus n = 19 (7.0%), P <0.001) and Week 48
(n = 21 (7.9%) versus n = 10 (3.7%), P = 0.023).
A significantly higher percentage of patients receiving the
13.3 mg/24 h patch compared with those receiving the
9.5 mg/24 h patch were ‘non-decliners’ based on the com-
bined criteria at Week 24 (n = 71 (26.8%) versus n = 44
(16.2%), P = 0.002). A trend toward a higher proportion of
‘non-decliners’ was observed with the higher-dose patch
compared with the 9.5 mg/24 h patch at Week 48 (n = 36
(13.6%) versus n = 24 (8.9%), P = 0.066).
Predictors of response
All covariates were available for all but four patients,
leaving a total of 532 subjects (264 in the 13.3 mg/24 hTable 1 Predictors of response from a stepwise logistic-regres
combined ‘non-decliner’ criteria








MMSEc MMSE ≤12c −
‘Non-decliners’




MMSEc MMSE ≤12c −
Weight, versus >80 kg Weight 50 to 80 kg −
Weight <50 kg
aPositive estimate indicates increased odds of response when increasing the value
means reduced odds of response. bTreatment effect compares 9.5 mg/24 h to 13.3
covariates were: treatment, gender, ADAS-cog score at DB-BL, ADCS-IADL score at D
>80 kg). ‘Improver’ = patient with an improvement from DB-BL in ADAS-cog score ≥
= patient with a change from DB-BL in ADAS-cog score ≤0 points and a change fr
Assessment Scale–cognitive subscale; ADCS-IADL, Instrumental domain of the Alzh
double-blind baseline; MMSE, Mini-Mental State Examination; na, not applicable b
only variables (effects) with a P-value <0.15 were included in the final model. Trea
Chi-Square test.patch group and 268 in the 9.5 mg/24 h patch group) to
be included in the stepwise regression model. Predictors
identified as being relevant for a response on the
combined ‘improver’ and ‘non-decliner’ criteria are
summarized in Table 1.
The probability of seeing improvement at Week 24 was
estimated to be higher for patients treated with the
13.3 mg/24 h versus the 9.5 mg/24 h patch (P = 0.0001).
Higher ADAS-cog score and lower ADCS-IADL score at
baseline (both indicating more severe impairment) also
resulted in an increased estimate of probability of
improvement (P = 0.017 and 0.050, respectively); con-
versely, an MMSE score ≤12 at baseline led to a
decreased estimate (P <0.0001). At Week 48, only male
gender and treatment with the 13.3 mg/24 h patch were
significant predictors (P = 0.014 and 0.021, respectively).
Similarly, the probability of seeing no decline at Week 24
was estimated to be higher for patients treated with the
13.3 mg/24 h versus the 9.5 mg/24 h patch (P= 0.002). At
Week 48, a baseline ADCS-IADL score indicating a more
severe disease status led to an increased estimate of the prob-
ability of no decline (P= 0.020), while an MMSE score
≤12 at baseline reduced the estimate (P = 0.040); treat-
ment with the 13.3 mg/24 h versus the 9.5 mg/24 h patch
was borderline non-significant (P = 0.058).sion model on combined ‘improver’ criteria and
ek 24 Week 48
timatea Pr > ChiSq Estimatea Pr > ChiSq
0.580 0.0001 −0.461 0.021
0.234 0.137 −0.040 0.014
0.044 0.017 −0.438 0.059
0.026 0.050 na na
0.854 <0.0001 na na
0.337 0.002 −0.270 0.058
0.218 0.094 na na
0.031 0.014 na na
na na −0.027 0.020
0.497 0.002 −0.351 0.040
0.363 0.068d −0.405 0.119d
0.208 0.344
of the covariate, or when in the given category. Negative estimated effect
mg/24 h rivastigmine patch. cAt DB-BL. dAll categories combined. Candidate
B-BL, MMSE score of ≤12 at DB-BL and weight category (<50, 50 to 80 and
4 points and a change from DB-BL in ADCS-IADL score ≥0 points; ‘non-decliner’
om DB-BL in ADCS-IADL score ≥0 points. ADAS-cog, Alzheimer’s Disease
eimer’s Disease Cooperation Study–Activities of Daily Living scale; DB-BL,
ecause effect not selected as relevant by the stepwise regression model –
tment was always retained within the model; Pr > ChiSq, P-value of the
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According to the present analysis, the proportion of
patients demonstrating a clinically relevant response
(improvement of at least four points on the ADAS-cog
and no decline on the ADCS-IADL) was more than two-
fold with the high-dose rivastigmine patch (13.3 mg/24 h)
relative to the lower dose (9.5 mg/24 h) at both Week 24
and Week 48. There was a significant difference between
dose groups in the proportion of ‘non-decliners’ using the
combined analysis (ADAS-cog and ADCS-IADL scales) to
Week 24, but this difference was not significant by Week 48.
At both time points (Weeks 24 and 48), the proportion of pa-
tients classified as responders (showing improvement or non-
decline) was more than 50% higher with the 13.3 mg/24 h
compared with the 9.5 mg/24 h rivastigmine patch.
There was a robust statistical association of the
13.3 mg/24 h rivastigmine patch with a significantly
greater likelihood of achieving improvement on combined
criteria compared with the 9.5 mg/24 h patch, supporting
the clinically meaningful benefit of this higher-dose patch.
In a population where all patients steadily decline in cog-
nition and function over the long term, the temporary sta-
bility achieved with either dose of rivastigmine patch
represents a valuable benefit to patients and their relatives
and/or caregivers.
The current analysis provides insights into the primary
analysis of the OPTIMA study. The primary study reported
deterioration from DB-BL to Week 48 on the ADAS-cog
and ADCS-IADL scale with both the 13.3 mg/24 h and the
9.5 mg/24 h patch [12]. Furthermore, in the primary ana-
lysis, the 13.3 mg/24 h patch group had a significant bene-
fit (statistically less deterioration) over the 9.5 mg/24 h
patch group from Week 16 up to Week 48 on the ADCS-
IADL scale, and showed a significant benefit at Week 24
(but not Week 48) using the ADAS-cog. When only
‘improvers’ are considered, this post-hoc analysis shows a
significant benefit for the 13.3 mg/24 h patch over the
9.5 mg/24 h patch on the ADAS-cog at Week 48. This
benefit of the 13.3 mg/24 h patch for the subset of
‘improvers’ was potentially masked by the much larger group
of patients who were ‘non-decliners’ or non-responders (that
is, showed deterioration) in the primary analysis. The oppos-
ite is seen when the effect of treatment on the ADCS-IADL
scale is considered. The post-hoc analysis (‘non-decliners’)
found a statistically significant difference between treat-
ment groups at Week 24, but not at Week 48, as was
found in the primary analysis (total population). There-
fore, the results from this post-hoc analysis offer a valuable
opportunity to evaluate the effect of different doses of
rivastigmine on different patient types.
To maximize the therapeutic benefit with ChEIs, the
optimal dose is tailored to each individual AD patient ac-
cording to disease stage and other clinical characteristics
[1]. Identifying the proportion of patients considered torespond to different doses of ChEI therapy during the
course of disease progression, as well as the characteristics
of these ‘responders’, will help physicians evaluate the clin-
ical benefit of different treatment regimens and assist them
in the choice of optimal therapy for their patients. In this
analysis, the proportion of patients who were ‘improvers’
or ‘non-decliners’ was higher at Week 24 than at Week 48
post-randomization on both measurement scales – reflecting
the progressive nature of the disease. The mean MMSE
score was 14.1 for patients in the 13.3 mg/24 h patch group
and 14.2 for patients in the 9.5 mg/24 h patch group, indicat-
ing that a large proportion of patients had reached a moder-
ate stage of AD by DB-BL [12].
Predictors of response analyses produced inconsistent
results (Table 1). Worse cognition or functional ability at
the start of the trial measured by the ADAS-cog or
ADCS-IADL, respectively, was associated with a sig-
nificantly greater chance of improvement (or lack of
decline) with rivastigmine after 24 weeks; when patients
declined to an MMSE score of less than 12 there was a
significantly reduced chance of improvement. Conversely,
the probability of response (or absence of decline) after
48 weeks tended to be higher with better cognition at
DB-BL (as indicated by either ADAS-cog for improvement,
and MMSE category for no-decline, respectively), again ac-
companied by the opposite effect on the ADCS-IADL. This
analysis was limited and biased by the design of the study.
Prospectively planned analyses for predictors of response
would be a useful approach in clinical trials of agents for
treatment of AD.
Reduced function compromises the patient’s ability to
live independently, is an important predictor of caregiver
burden [15] and is a strong risk factor for nursing home
placement or institutionalization [16-18]. In turn, nurs-
ing home placement has a marked influence on the
overall costs of dementia management [18]. By measur-
ing both cognitive and functional decline, physicians
gain a more complete picture of the likely impact of the
disease and the available treatments on the patient, their
caregiver and the healthcare system in general.Conclusions
The therapeutic benefit of the higher-dose 13.3 mg/24 h
versus the 9.5 mg/24 h rivastigmine patch derives from a
significant increase in the number of ‘improvers’ main-
tained over 48 weeks. The proportion of patients classi-
fied as ‘non-decliners’ (who experienced improvement or
no decline) at 48 weeks with the 13.3 mg/24 h patch
was also numerically higher than that observed with the
9.5 mg/24 h patch. This stability is an important benefit
in a declining population. Predictors of response analyses
produced contradictory results that were not easy to inter-
pret. Therefore, further research is warranted.
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